Diamonds and Dogs
3/28/16
Time to get rid of your migraine with today's diamond. Alder Biopharmaceuticals (ALDR) is surging over $8 or 50% after announcing positive top line data for their clinical trial migraine preventative drug. The drug, ALD403, reduced migraine days by at least 75% in 41% of patients who took the highest dose. Nearly 13 million patients across the U.S. are candidates for migraine prevention drugs, making it an attractive and potentially lucrative market for pharmaceutical companies. Plus, Alder's drug sets itself apart thanks to the fact the injection need only be taken every few months instead of every month. Here's to more good news coming from Alder Biopharmaceuticals.
Someone opened Pandora's box on today's dog. Pandora Media (P) is tumbling 12% not far from the 52 week low after replacing the CEO with the founder this weekend. The Internet music service provider has been unprofitable each year since its IPO in 2011, losing more money not less with each new listener. In fact, about half of Pandora's revenue goes toward paying for the rights to play songs to their 80 million listeners. Let's hope the company finds a solution so the music doesn't have to die.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.